EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412). (12th June 2019) - Diefenbach, C.S.; Hong, F.; Ambinder, R.; Cohen, J.; Robertson, M.; David, K.; Advani, R.; Fenske, T.; Barta, S.; Palmisano, N.; Svoboda, J.; Morgan, D.; et al.